| |
| 29th Dec 2008 |
| |
|
| |
Veeda Oncology®, a
full service global Oncology CRO
with facilities in North America,
Europe and India, has been awarded
$3 million of new clinical research
programs for the Veeda Oncology
Network of Sites during the past 30
days.
The awarded work will be conducted
at sites in North America and
includes services for site
feasibility, site management,
project management, quality
assurance, scientific review and
medical support.
According to Matt Bowman, President
and CEO of Veeda Oncology, “this new
business is directly related to our
ability to provide qualified
oncology sites with the capability
to begin accruing patients very
rapidly”.
Veeda Oncology is a global Oncology
CRO with operations in India,
Eastern Europe, Western Europe and
the US. The company is a full
service Oncology CRO for Phase I
through Phase IV studies with the
unique capability of providing rapid
and strong global patient accrual
with an effective cost structure.
Veeda Oncology is part of the Veeda
Group that includes Veeda Clinical
Research (Veeda CR), which is a
leading CRO specializing in the
early clinical development of drugs.
With state of the art clinical
pharmacology units in the UK, Europe
and India, fully accredited GLP
Laboratories and an established
Biometrics team in Belgium and
India, Veeda CR is able to offer
clients a full range of phase I and
IIa services. In addition, Veeda CR
maintains an extensive database of
volunteers from which to accrue
appropriate subjects in a timely
fashion. |
| |
| For further information,
please contact: |
| |
| USA |
| Matt Bowman |
| Tel: (614) 643-1484 |
| matt.bowman@veedaoncology.com |
| |
| India |
| Priyanka Shah |
| Tel: +91 9879068886 |
| priyanka.shah@veedacr.com |
| |
| To know more about Veeda services or if you have any query please click
here to contact us |
| |
|
| |